Adlai Nortye Group Ltd. (ANL)
NASDAQ: ANL · Real-Time Price · USD
15.22
-0.30 (-1.93%)
At close: Sep 17, 2026, 4:00 PM EDT
15.28
+0.06 (0.39%)
After-hours: Sep 17, 2026, 4:50 PM EDT
Adlai Nortye Group Employees
Adlai Nortye Group had 109 employees as of December 31, 2025. The number of employees decreased by 14 or -11.38% compared to the previous year.
Employees
109
Change (1Y)
-14
Growth (1Y)
-11.38%
Revenue / Employee
$165,651
Profits / Employee
-$206,688
Market Cap
980.14M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 109 | -14 | -11.38% |
| Dec 31, 2024 | 123 | -4 | -3.15% |
| Dec 31, 2023 | 127 | -2 | -1.55% |
| Jun 30, 2023 | 130 | - | - |
| Mar 31, 2023 | 129 | - | - |
| Dec 31, 2022 | 129 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Kura Oncology | 260 |
| Sana Biotechnology | 142 |
| MoonLake Immunotherapeutics | 130 |
| Janux Therapeutics | 113 |
| Cybin | 100 |
| SpyGlass Pharma | 76 |
| Apnimed | 65 |
| Corvus Pharmaceuticals | 37 |
ANL News
- 1 day ago - Adlai Nortye Group Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 7 days ago - Adlai Nortye initiated with a Buy at Jefferies - TheFly
- 9 days ago - Adlai Nortye doses first patient in AN4035 trial - TheFly
- 9 days ago - Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC - GlobeNewsWire
- 9 days ago - Adlai Nortye assumed with a Buy at Lucid Capital - TheFly
- 4 weeks ago - Adlai Nortye Group Earnings release: Q2 2026 - Filings
- 4 weeks ago - Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress - GlobeNewsWire
- 6 weeks ago - Adlai Nortye submits clinical trial notification to Australia TGA for AN4035 - TheFly